Advanced

FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations

Perry, D.; Berntorp, Erik LU ; Tait, C.; Dolan, G.; Holme, P. A.; Laffan, M.; Lassila, R.; Mumford, A.; Pasi, J. and Wilde, J., et al. (2010) In Haemophilia 16(1). p.80-89
Abstract
In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing activity (FEIBA) prophylaxis has been shown to reduce the frequency of bleeding by up to 85% and to improve patient quality of life. FEIBA is well tolerated; the incidence of thrombotic events and of allergic reactions is extremely low. The concept of prophylaxis in haemophilia patients with inhibitors is relatively new and some clinicians may be unsure of how to use FEIBA in this context. These treatment recommendations, based on published evidence plus the collective experience of a group of haematologists (with practical knowledge of managing inhibitor patients with FEIBA prophylaxis), are intended to provide guidance to clinicians considering... (More)
In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing activity (FEIBA) prophylaxis has been shown to reduce the frequency of bleeding by up to 85% and to improve patient quality of life. FEIBA is well tolerated; the incidence of thrombotic events and of allergic reactions is extremely low. The concept of prophylaxis in haemophilia patients with inhibitors is relatively new and some clinicians may be unsure of how to use FEIBA in this context. These treatment recommendations, based on published evidence plus the collective experience of a group of haematologists (with practical knowledge of managing inhibitor patients with FEIBA prophylaxis), are intended to provide guidance to clinicians considering initiating and maintaining patients on FEIBA prophylaxis with specific focus on practical aspects of patient selection, dosing, monitoring and stop criteria. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
haemophilia, FEIBA, bypassing agents, factor VIII inhibitors, inhibitors, prophylaxis
in
Haemophilia
volume
16
issue
1
pages
80 - 89
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000273179800012
  • scopus:73949133069
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2009.02104.x
language
English
LU publication?
yes
id
3f71856a-085d-49b7-a78e-b5c74e576083 (old id 1533749)
date added to LUP
2010-01-27 14:49:08
date last changed
2018-05-29 12:19:10
@article{3f71856a-085d-49b7-a78e-b5c74e576083,
  abstract     = {In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing activity (FEIBA) prophylaxis has been shown to reduce the frequency of bleeding by up to 85% and to improve patient quality of life. FEIBA is well tolerated; the incidence of thrombotic events and of allergic reactions is extremely low. The concept of prophylaxis in haemophilia patients with inhibitors is relatively new and some clinicians may be unsure of how to use FEIBA in this context. These treatment recommendations, based on published evidence plus the collective experience of a group of haematologists (with practical knowledge of managing inhibitor patients with FEIBA prophylaxis), are intended to provide guidance to clinicians considering initiating and maintaining patients on FEIBA prophylaxis with specific focus on practical aspects of patient selection, dosing, monitoring and stop criteria.},
  author       = {Perry, D. and Berntorp, Erik and Tait, C. and Dolan, G. and Holme, P. A. and Laffan, M. and Lassila, R. and Mumford, A. and Pasi, J. and Wilde, J. and Will, A. and Yee, T. T.},
  issn         = {1351-8216},
  keyword      = {haemophilia,FEIBA,bypassing agents,factor VIII inhibitors,inhibitors,prophylaxis},
  language     = {eng},
  number       = {1},
  pages        = {80--89},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2009.02104.x},
  volume       = {16},
  year         = {2010},
}